Credit Suisse analyst Kennen MacKay raised his price target for Puma Biotechnology by $57 to $111 after increasing his sales expectations for neratinib. The biotech focused on cancer treatment closed yesterday up $2.98 to $67.97. The FDA's acceptance of Puma's New Drug Application for neratinib for patients with early stage HER2-overexpressed/amplified breast cancer is a "key de-risking event," MacKay tells investors in a research note. Further, the analyst says his doctor checks suggest "improved physician sentiment" towards neratinib and growing awareness surrounding the use of Imodium prophylaxis to manage diarrhea. He keeps a Buy rating on shares of Puma Biotechnology.